SG Americas Securities LLC Cuts Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

SG Americas Securities LLC lessened its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 73.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,724 shares of the company's stock after selling 121,292 shares during the quarter. SG Americas Securities LLC owned about 0.05% of Deciphera Pharmaceuticals worth $705,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in Deciphera Pharmaceuticals by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company's stock worth $26,000 after acquiring an additional 997 shares in the last quarter. Compass Wealth Management LLC bought a new stake in shares of Deciphera Pharmaceuticals during the fourth quarter worth about $70,000. Advisor Group Holdings Inc. grew its holdings in shares of Deciphera Pharmaceuticals by 78.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 4,331 shares of the company's stock worth $71,000 after purchasing an additional 1,898 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Deciphera Pharmaceuticals during the first quarter worth about $57,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Deciphera Pharmaceuticals by 144.1% during the second quarter. Tower Research Capital LLC TRC now owns 6,817 shares of the company's stock worth $96,000 after purchasing an additional 4,024 shares during the last quarter. Institutional investors and hedge funds own 70.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DCPH. JPMorgan Chase & Co. boosted their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a "neutral" rating in a report on Wednesday, March 20th. Stifel Nicolaus upped their target price on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, February 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Deciphera Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.00.

Insider Transactions at Deciphera Pharmaceuticals

In related news, EVP Matthew L. Sherman sold 2,435 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $14.47, for a total value of $35,234.45. Following the completion of the sale, the executive vice president now directly owns 94,079 shares of the company's stock, valued at approximately $1,361,323.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.43% of the stock is owned by insiders.

Deciphera Pharmaceuticals Trading Up 0.7 %

DCPH stock traded up $0.10 during trading on Wednesday, hitting $15.29. The company had a trading volume of 429,433 shares, compared to its average volume of 544,375. The business has a 50-day moving average of $15.56 and a 200-day moving average of $14.06. Deciphera Pharmaceuticals, Inc. has a one year low of $9.90 and a one year high of $17.73. The stock has a market cap of $1.24 billion, a PE ratio of -6.68 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. The firm had revenue of $48.30 million for the quarter, compared to analysts' expectations of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company's revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.60) EPS. Research analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current year.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.